• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[一种用于计算多发性骨髓瘤生存率的数学模型的可重复性]

[Reproducibility of a mathematical model for calculating survival in multiple myeloma].

作者信息

Pasqualetti P, Casale R, Colantonio D

出版信息

Medicina (Firenze). 1989 Apr-Jun;9(2):182-4.

PMID:2811644
Abstract

The reliability of the mathematical model for calculating survival proposed by Merlini, Waldenstrom e Jayakar (1980) was tested in a group of 80 patients with multiple myeloma. The observed and calculated survivals were compared using univariate regression analysis. The results show that a significant (p less than 0.001) relationship between observed and calculated survival exists in the study patient group. These observations confirm that this useful and reliable clinical staging system can be a basis for individualization of a new treatment approach for each stage in order to reach an optimal treatment for multiple myeloma patients.

摘要

对Merlini、Waldenstrom和Jayakar(1980年)提出的用于计算生存率的数学模型的可靠性,在一组80例多发性骨髓瘤患者中进行了测试。使用单变量回归分析比较了观察到的和计算出的生存率。结果表明,在研究患者组中,观察到的和计算出的生存率之间存在显著关系(p小于0.001)。这些观察结果证实,这个有用且可靠的临床分期系统可以作为为每个阶段制定新治疗方法个体化的基础,以便为多发性骨髓瘤患者实现最佳治疗。

相似文献

1
[Reproducibility of a mathematical model for calculating survival in multiple myeloma].[一种用于计算多发性骨髓瘤生存率的数学模型的可重复性]
Medicina (Firenze). 1989 Apr-Jun;9(2):182-4.
2
[Evaluation of a morphologic staging method (myeloma progression score) in multiple myeloma].
Medicina (Firenze). 1989 Jul-Sep;9(3):280-2.
3
Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.多发性骨髓瘤的分类与预后评估。一项关于生存及化疗反应与免疫类型、20个单一预后因素、15种临床分期系统及6种形态学分类之间关系的回顾性研究。
Panminerva Med. 1991 Apr-Jun;33(2):93-110.
4
International staging system for multiple myeloma.多发性骨髓瘤国际分期系统
J Clin Oncol. 2005 May 20;23(15):3412-20. doi: 10.1200/JCO.2005.04.242. Epub 2005 Apr 4.
5
[Comparative study of 2 prognostic classification systems for myeloma and examination of the correlation between initial bone marrow plasmacytosis and prognosis. A propos of a homogeneous population of 50 patients followed from diagnosis to death].骨髓瘤2种预后分类系统的比较研究及初始骨髓浆细胞增多与预后相关性的检测。关于50例从诊断至死亡的同质患者群体
Nouv Rev Fr Hematol (1978). 1983;25(5):311-7.
6
[Prognostic evaluation in multiple myeloma. Relationship between immunological types, single prognostic factors, clinical staging systems, morphological classification systems and survival].
Ann Ital Med Int. 1990 Jul-Sep;5(3 Pt 1):195-204.
7
A comparison of two staging systems for myeloma.两种骨髓瘤分期系统的比较。
Nouv Rev Fr Hematol (1978). 1981;23(2):107-10.
8
[Prognostic factors in multiple myeloma. Selection using multivariate analysis].
Recenti Prog Med. 1989 Oct;80(10):543-6.
9
Prognostic factors in multiple myeloma: selection using Cox's proportional hazard model.
Biomed Pharmacother. 1996;50(1):29-35. doi: 10.1016/0753-3322(96)85095-5.
10
Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.利用游离β2微球蛋白的HLA I类重链血清水平以及IgM或血小板计数对活动性疾病的多发性骨髓瘤患者进行分期。
Blood Cells Mol Dis. 2009 Jan-Feb;42(1):71-6. doi: 10.1016/j.bcmd.2008.09.003. Epub 2008 Nov 7.